Worth reading
74In focus
Scored from 4 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFiscal year ending March 2026, full year9 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥69,326 million+3.3%
Operating profit¥9,209 million+4.5%
Ordinary income¥9,470 million+5.8%
Net income¥5,923 million-8.4%
Gross Profit Margin45.4%
Operating profit margin13.3%
Selling, general and administrative expenses¥22,241 million
Full-year earnings forecast
Fiscal year ending March 2027
Net Sales
¥68,000 million
Operating profit
¥7,000 million
Ordinary income
¥6,900 million
Profit attributable to owners of the parent
¥4,500 million
Earnings per share
¥164.35
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales99.0%
Operating profit96.9%
Ordinary income100.7%
Profit attributable to owners of the parent91.1%
Earnings per share91.1%
By segment
Semiconductor-related revenue103.9%
Measurement and weighing instruments revenue94.7%
Medical and healthcare equipment revenue102.6%
Semiconductor-related operating profit105.2%
Measurement and weighing instruments operating profit96.8%
Medical and healthcare equipment operating profit91.1%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Revenue and operating profit both fell slightly short of the full-year forecasts. Net income fell short of the plan.Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Extraordinary Losses¥552 millionFactorsCosts related to corrective measures for violations of the Measurement Act
- Extraordinary Losses¥243 millionFactorsEmbezzlement losses at a consolidated subsidiary in South Korea
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
- ¥150AssumptionsAssumed exchange rate (U.S. dollar)
- ¥1.9AssumptionsAssumed exchange rate (Russian ruble)
New initiatives
- Strengthen the global sales and service structure
- Expand the product lineup through new product development
- Strengthen sales in priority regions
- Expand target industries and application fields
- Reduce costs and expand sales of high-value-added products
Key KPIsA metric the company considers important as a management benchmark.
- ROE12.9 %Year on year against the same period last year-3.2 percentage points
Segment results
- Semiconductor-Related BusinessNet Sales¥11,114 million (YoY -9.6%)Operating profit¥3,628 million (YoY -12.0%)
- Measurement and weighing instrumentsNet Sales¥31,545 million (YoY +2.9%)Operating profit¥3,387 million (YoY +25.2%)
- Medical and health equipmentNet Sales¥26,667 million (YoY +10.5%)Operating profit¥4,009 million (YoY -2.4%)
Medium-term management plan targets
ThemeRedefining business value and rebuilding the foundation
Target fiscal yearFiscal year ending March 2028
Original plan
Net Sales¥80.0 billion
Operating profit¥11.7 billion
Operating profit margin14.6%
Revised plan
Net Sales¥75.5 billion
Operating profit¥9.9 billion
Operating profit margin13.1%
Comparison with actual resultsFor the fiscal year ended March 2026, revenue was ¥69.3 billion and operating profit was ¥9.2 billion, ¥700 million and ¥300 million below the respective initial plan figures.
Annual Dividend
Fiscal year ending March 2026
Annual¥55
Interim¥25
End of period¥30
Forecast for the fiscal year ending March 2027
Annual¥60
Interim¥30
End of period¥30
Payout ratio
Fiscal year ending March 202636.5 %
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Fiscal year ending March 2026, full year |
| Net Sales | ¥69,326 million (YoY +3.3%) |
| Operating profit | ¥9,209 million (YoY +4.5%) |
| Ordinary income | ¥9,470 million (YoY +5.8%) |
| Net income | ¥5,923 million (YoY -8.4%) |
| Gross Profit Margin | 45.4% |
| Operating profit margin | 13.3% |
| Selling, general and administrative expenses | ¥22,241 million |
| Full-year earnings forecast | Fiscal year ending March 2027 Net Sales ¥68,000 million / Operating profit ¥7,000 million / Ordinary income ¥6,900 million / Profit attributable to owners of the parent ¥4,500 million / Earnings per share ¥164.35 |
| Progress against full-year forecast | Net Sales 99.0% / Operating profit 96.9% / Ordinary income 100.7% / Profit attributable to owners of the parent 91.1% / Earnings per share 91.1% / By segment Semiconductor-related revenue 103.9% / Measurement and weighing instruments revenue 94.7% / Medical and healthcare equipment revenue 102.6% / Semiconductor-related operating profit 105.2% / Measurement and weighing instruments operating profit 96.8% / Medical and healthcare equipment operating profit 91.1% |
| Self-assessment against the plan | Revenue and operating profit both fell slightly short of the full-year forecasts. Net income fell short of the plan. |
| Segment results | Segment Semiconductor-Related Business / Net Sales ¥11,114 million (YoY -9.6%) / Operating profit ¥3,628 million (YoY -12.0%), Segment Measurement and weighing instruments / Net Sales ¥31,545 million (YoY +2.9%) / Operating profit ¥3,387 million (YoY +25.2%), Segment Medical and health equipment / Net Sales ¥26,667 million (YoY +10.5%) / Operating profit ¥4,009 million (YoY -2.4%) |
| Breakdown of Factors Affecting the Change | Factors Costs related to corrective measures for violations of the Measurement Act / Amount ¥552 million / Category Extraordinary Losses, Factors Embezzlement losses at a consolidated subsidiary in South Korea / Amount ¥243 million / Category Extraordinary Losses |
| Key KPIs | Indicator name ROE / Value 12.9 % / Year on year against the same period last year -3.2 percentage points |
| Assumptions Underlying the Business Outlook | Assumptions Assumed exchange rate (U.S. dollar) / Value ¥150, Assumptions Assumed exchange rate (Russian ruble) / Value ¥1.9 |
| Medium-term management plan targets | Theme Redefining business value and rebuilding the foundation / Target fiscal year Fiscal year ending March 2028 / Original plan Net Sales ¥80.0 billion / Operating profit ¥11.7 billion / Operating profit margin 14.6% / Revised plan Net Sales ¥75.5 billion / Operating profit ¥9.9 billion / Operating profit margin 13.1% / Comparison with actual results For the fiscal year ended March 2026, revenue was ¥69.3 billion and operating profit was ¥9.2 billion, ¥700 million and ¥300 million below the respective initial plan figures. |
| Annual Dividend | Fiscal year ending March 2026 Annual ¥55 / Interim ¥25 / End of period ¥30 / Forecast for the fiscal year ending March 2027 Annual ¥60 / Interim ¥30 / End of period ¥30 |
| Payout ratio | Fiscal year ending March 2026 36.5 % |
| New initiatives | Strengthen the global sales and service structure, Expand the product lineup through new product development, Strengthen sales in priority regions, Expand target industries and application fields, Reduce costs and expand sales of high-value-added products |
Items this document does not state (11)
Results for the three months of the current quarterUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookFinancial targetsAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The shortfall in revenue and operating profit for the fiscal year ended March 2026 was primarily attributable to restrained investment related to U.S. EVs and the impact of tariffs in the measurement and weighing instruments business, as well as the reaction to strong demand in the semiconductor-related business. Net income declined because ¥552 million in costs related to corrective measures for violations of the Measurement Act and ¥243 million in embezzlement losses at a consolidated subsidiary in South Korea were recorded as extraordinary losses. The forecast for lower revenue and lower profit in the fiscal year ending March 2027 reflects a temporary adjustment in demand in the Chinese market, restrained EV-related investment, and cost increases resulting from U.S. tariff policy and inflation overseas, among other factors.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.